info@lifesciencecollaborative.org

CONNECTING LEADERS

In Science And Business

UPCOMING EVENTS

No event found!

WHO WE ARE

The Life Sciences Collaborative is a select group of industry veterans and executives from the pharmaceutical, biotechnology, and medical device sectors and industry service providers who share a common vision of increasing the success.

LSC activities are built around small, informal, monthly breakfast educational and networking meetings. These sessions focus on topics around innovation and investment, including industry trends, practical issues related to growing and managing innovative businesses, and best practices.

OUR PARTNERS

MISSON STATEMENT

The mission of the Life Sciences Collaborative is to promote connectivity among leaders in emerging life sciences businesses through networking, education, training, and mentorship with the goal of advancing professionals.

LSC is a volunteer organization. It is neither sponsorship nor membership dues driven. If you are interested in participating in LSC’s monthly breakfast meetings, please contact us.

MISSON STATEMENT

The mission of the Life Sciences Collaborative is to promote connectivity among leaders in emerging life sciences businesses through networking, education, training, and mentorship with the goal of advancing professional.

LSC EVENTS

The meetings also include presentations by emerging companies, providing them with
opportunities to get expert feedback on their technologies and to expand their networks.

No event found!
Load More

LSC MEMBERS

CEOs, Directors, Private Equity and Venture Partners, Angel Investors

Members may have successful track record leading public or private companies.

Glenn Whaley

Position: Chief Financial Officer at Immunic Therapeutics (Nasdaq:IMUX)
Categories: 3. MEMBERS, LSC – New Jersey

Glenn Whaley

Chief Financial Officer at Immunic Therapeutics (Nasdaq:IMUX)

Guanghui Hu

Categories: 3. MEMBERS, LSC – New Jersey

Guanghui Hu

Ihor Terleckyj, Ph.D.

Position: Chief Executive Officer; CuRAGE Therapeutics
Categories: LSC – New Jersey

Ihor Terleckyj, Ph.D.

Chief Executive Officer; CuRAGE Therapeutics

Ira Spector

Position: CEO at SFA Therapeutics, Inc
Categories: 3. MEMBERS, LSC – New Jersey

Ira Spector

CEO at SFA Therapeutics, Inc

Jerry Ruddle

Position: CEO at NewIV Medical Corp
Categories: 3. MEMBERS, LSC – New Jersey

Jerry Ruddle

CEO at NewIV Medical Corp

Joe Camaratta

Position: President and CEO at Quantaras
Categories: 3. MEMBERS, LSC – New Jersey

Joe Camaratta

President and CEO at Quantaras

John Cavan

Position: Former CFO – Hepion Pharmaceuticals
Categories: 3. MEMBERS, 3. MEMBERS, Boston, MA, LSC – New Jersey

John Cavan

Former CFO – Hepion Pharmaceuticals

John Gregg

Position: Chairman and CEO at BalinBac Therapeutics, Inc.
Categories: 3. MEMBERS, LSC – New Jersey

John Gregg

Chairman and CEO at BalinBac Therapeutics, Inc.

John Pennett, CPA

Position: Eisner Amper
Categories: 2. PLANNING COMMITTEE, 2. PLANNING COMMITTEE, 3. MEMBERS, Boston, MA, LSC – New Jersey

John Pennett, CPA

Eisner Amper

Joseph Armstrong, PhD

Position: Chief Operating Officer at TCG GreenChem, Inc.
Categories: 2. PLANNING COMMITTEE, LSC – New Jersey

Joseph Armstrong, PhD

Chief Operating Officer at TCG GreenChem, Inc.

WHAT OUR MEMBERS SAY

“The LSC has given me instant access to a number of subject matter experts as well new connections to colleagues up and down the East Coast!”

Mike Webb
President and CEO, CXL Ophthalmics

“I learn something new and valuable at every LSC event. I’ve been able to make new connections & friends in every aspect of the ecosystem.” 

Mark Moody PhD 
COO, Activate Therapeutics

“What I find unique about the LSC is the multiple new connections I’ve been able to make in different aspects of our ecosystem.” 

Mark Tepper PhD
CEO Eumentis Therapeutics

“Joining the LSC was more proof that interacting with peers from the broad life sciences ecosystem is a great vehicle to further enrich my knowledge and stimulate my thinking. I am grateful to the organizers for driving this initiative.”

David Barone
Principal, Boston MedTech Advisors, Inc.